ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Mechanically Triggered DNA Nanovehicles for Targeted Dual-Drug Cancer Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Stimuli-responsive dual-drug delivery systems enable precise therapeutic control by co-releasing multiple agents, enhancing synergy while reducing dosage and side effects. Mechanical dysregulation is a hallmark of various diseases, yet force-responsive platforms remain rare. Here, we introduce a DNA-based mechanical nanovehicle that releases two anticancer drugs-TMPyP4 and doxorubicin-in response to tensile forces generated by integrin receptors at cell-cell junctions. The cholesterol-modified DNA constructs anchor to the cell membrane and undergoes force-induced structural changes, triggering rapid drug release under defined mechanical conditions. Our studies demonstrated selective activation in HeLa and MCF-7 cancer cells, achieving potent cytotoxicity while minimizing off-target effects in low-tension HEK293T cells. This modular platform integrates mechanosensing, real-time force visualization, and targeted therapy, establishing a new class of mechanoresponsive dual-drug delivery systems for safer and more effective cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.